Mind Medicine (MindMed) Inc. (MNMD) — MindMed management presented at the Jefferies Global Healthcare Conference in London, part of a run of investor appearances (Stifel, Jefferies, Evercore and Piper Sandler) through November and December.
The company reiterated that its pivotal Phase 3 trials of MM120 (lysergide) in generalized anxiety disorder and major depressive disorder remained on track, with topline readouts expected across 2026 and roughly $209 million in cash following an October raise.
Source: businesswire.com
For the rest of that week's sector news, read our week in review.